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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S90Purpose: Lubricin (aka. PG4, superﬁcial zone protein) is secreted by
synovial ﬁbroblast and chondrocyte of superﬁcial layer of articular carti-
lage, where it maintains a lubricated and friction-less surface. We specu-
lated that that degradation lubricin by neutrophil elastase whose
expression is up-regulated following inﬂammatory insults and the release
of these fragments into the synovial cavity might be an early biomarker of
joint diseases. We therefore set-out to develop an ELISA measuring
protease derived fragments of lubricin.
Methods: Human cartilage and synovial membrane were in vitro digested
by a variety of MMPs, aggrecanase, cysteine proteinase and serine
proteinase respectively, including MMP2, MMP12, MMP13, ADAMTS4,
ADAMTS5, Cathepsin B and Neutrophil Elastase. The proteolysis products
were analyzed by mass spectrometry and evaluated using the Mascot
database. A cleavage fragment (neoepitope) of lubricin was identiﬁed. A
peptidewas generated, which conjugated to KLH- and used as immunogen.
Six eight-week old Balb/C mice were immunized sequentially and the
immuno-reactivity towards the lubricin neoepitopewas tested after 3rd, 4th
and 5th immunization. Mice with best reactivity were selected and spleens
were isolated and fused with SP2/O cells. The hybridomas were subse-
quently cloned by classic limiting dilution method, and subclones were
produced. The best monoclonal antibody was selected based on following
criteria: speciﬁcity towards neoepitope using a speciﬁc peptide (positive
control), elongated peptide (negative control) and nonsense peptide
(negative control). Furthermore, the Mabs were tested for reactivity in
native samples, such as serum, urine, synovial ﬂuid and culture superna-
tants. A competition ELISA was developed using the best Mab with
following procedure: a 96-well streptavidin-coated plate was coated with
1ng/ml Biotin labeled lubricin neoepitope for 30 min at 20C, at 300 rpm.
The plate was then washed 5 times with standard wash solution. Standard
and samples were added 20ul/well, followed by the addition of 100ul/well
peroxidase labeled antibody and incubated onvernight (201 h) at 4C, at
300 rpm. After that, the wells were washed 5 times and incubated with
100ul/well TMB at 20C, at 300 rpm for 15 min. Then 100ul/well stop
solution was added and the colorimetric reaction was measured at 450nm
with reference at 650nm. The ELISAwas used to characterize the release of
the fragments from human cartilage explants.
Likewise, synovial ﬂuid samples from OA patients were measured (n¼15).
Results: A speciﬁc lubricin neoepitope with C-terminal cleavage site
generated by Neutrophil Elastase was identiﬁed by mass spectrometry.
Blasting results showed that it was speciﬁc for human lubricin. All mice had
strong immunization response to the neoepitope linked KLH-immunogen.
After serial subcloning, one antibody producing clone, Mab-13H1, with IgG
[[Unsupported Character - L]] isotype was obtained and characterized. It
had speciﬁc response to the speciﬁc peptide, but not toward the elongated
peptide. Thus the Mab-13H1 was speciﬁc for the cleavage site. The
competitiveELISA showedgood technical performance:1)measuring range
from 0.27ng/ml to 200ng/ml; 2) intra- and inter-assay CVs: 10% and 15%; 3)
Dilution recovery of human serum samples: 82.8%-112%; 4) interference:
blocked by adding liquid-II. The neoepitope was found in synovial ﬂuid of
patients with range from 1,16ng/ml to 23,042ng/ml (unadjusted values).
Conclusion: We identiﬁed and developed a new competitive ELISA for
measuring of lubricin neoepitope primarily from synovial membrane. We
found measurable amounts in synovial ﬂuid of RA patients, indicating that
this could be a novel biomarker of early cartilage loss.
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TWO NOVEL DIAGNOSTIC BIOMARKERS OF CARTILAGE DEGRADATION
AND CONNECTIVE TISSUE INFLAMMATION ARE PREDICTIVE OF
RADIOGRAPHIC DISEASE PROGRESSION
A.-C. Bay-Jensen 1, S. Wichuk 2, I. Byrjalsen 1, M.A. Karsdal 1,
W.P. Maksymowych 2. 1Nordic BioSci. A/S, Herlev, DENMARK; 2Div. of
Rheumatology, University of Alberta, AB, CANADAPredictive value for radiographic progression of serum C2M and C3M
High C2M (n¼94) High C3M (n¼
Positive predictive value 0.44 (0.27 - 0.62) 0.59 (0.41 - 0.7
Negative predictive value 0.70 (0.57 - 0.81) 0.57 (0.43 - 0.6Purpose: Cartilage degradation and inﬂammation of connective tissue are
key events in inﬂammatory and non-inﬂammaory arthropathies, such as
osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis
(AS). Presently there are no prognostic tools available for measuring these
tissue related processes, which are often the target of intervention.
Inﬂammation induces an increase in collagenases. An elevated level of
collagenases will lead to increased degradation of the disease affected
tissues, e.g. cartilage and synovial tissue. Type II collagen is the primary
protein component of cartilage and type III collagen is one of the major
proteins of many connective tissues (e.g. synovial membrane); thus they
are obvious targets for the action of collagenases. The objective of the
study was to investigate whether those fragments could be used as
predictive biomarkers of radiographic disease progression.
Method: Serum samples were collected from patient suffering from AS
(n¼124) at baseline and 2-3 month treatment follow-up. Standard AS
clinical outcome scores were collected: BASDAI (health questionnaire) and
mSASSS (radiographic scoring). Progressors were deﬁned as having new
vertebra syndesmophytes over a two year period. Serum levels of type II
collagen degradation was measured by the C2M competitive ELISA, and
type III collagen degradation by the C3M ELISA. Serum hsCRP was likewise
measured. Logistic regression and CART were used to analyze the prog-
nostic value of the markers individually or in combination.
Results: Both cartilage and connective tissue degradation fragments, C2M
and C3M, were signiﬁcantly elevated in AS patient serum samples
compared to healthy controls (p<0.0001). The area under the curves of
C2M and C3M, respectively, were 70% and 81% for AS. C3M correlated
signiﬁcantly with AS score BASDAI and mSASSS (p<0.01). C2M did not
show the same correlations. A combination of the two markers could
predict 80% of those who was deﬁned as progressors, with a negative
predictive value of 61%.
Conclusion:Present study is theﬁrst to showthat the twonovelbiomarkers
of cartilage andconnective tissuedegradation addadditional information to
the understanding of the diagnosis and progression of arthropathies. No
other clinical score or biomarker possesses these properties.
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GLA RICH PROTEIN (GRP) IS ASSOCIATED TO OSTEOARTHRITIS BEING
HIGHLY ACCUMULATED IN THE JOINT TISSUES AND SYNOVIAL FLUID
S.I. Cavaco 1, C.B. Viegas 1,2, R. Marta 1, R. Acácio 3, J. Silva 3, J.L. Morera 4,
A. Teixeira 4, E. Smit 5, M. Herfs 5, C. Vermeer 5, D.C. Simes 1,2. 1CCMAR,
Algarve Univ., Faro, PORTUGAL; 2GenoGla Diagnostics, Faro, PORTUGAL;
3 Faro Hosp., Dept. of Orthopedic and Traumathology, Faro, PORTUGAL;
4 Faro Hosp., Dept. of Anatomical Pathology, Faro, PORTUGAL; 5VitaK,
Maastricht Univ., Maastricht, NETHERLANDS
Purpose: The newly discovered Gla-rich protein (GRP) is a vitamin K-
dependent protein with high calcium-binding ability through its Gla
residues. It was recently shown to be highly expressed and accumulated in
rat cartilage and bone, and was suggested to be an important new player in
the complexity of phenotypes involving connective tissue mineralization.
With this work we aim to unveil the relationship between GRP and the
molecular mechanisms involved in cartilage degradation and calciﬁcation
associated with osteoarthritis (OA).
Methods: To investigate a possible involvement of GRP in OA processes we
have analyzed samples of synovial membrane, cartilage, subchondral bone
and synovial ﬂuid, collected from OA patients at the time of total knee
arthroplasty. Western blot and immunohistochemistry (IHC) techniques
were performed using polyclonal antibodies against total GRP (CTerm-
GRP) and the carboxylated form of GRP (anti-cGRP). Protein extracts from
cartilage and synovial ﬂuid were also analyzed using 2-D electrophoresis
and GRP was detected by Western blot. The presence of the four GRP
isoforms previously described in mouse was analyzed in human joint
tissues using speciﬁc primers.94) High hsCRP (n¼87) High C2M & high C3M (n¼33)
5) 0.33 (0.17 - 0.53) 0.80 (0.52 - 0.96)
9) 0.74 (0.60 - 0.84) 0.61 (0.36 - 0.83)
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S91Results: GRP was detected by IHC throughout all mineralized areas in non-
decalciﬁed tissue samples, both in calciﬁed cartilage and bone, as well as in
the hyaline cartilage and chondrocytes. Decalciﬁcation of those tissue
sections resulted in the loss of GRP signal associated with the mineralized
matrixes, and clearly identiﬁed GRP within osteoblasts and osteocytes in
bone, in agreementwith GRP pattern of accumulationpreviously seen in rat
skeletal tissues. Evidences for GRP accumulation in the osteoclasts were
also seen, but this result needs further conﬁrmation. In the synovial
membrane, GRP was found highly associated with speciﬁc cell types at the
synovial lining layer, within synoviocytes and in endothelial cells of capil-
laries and sporadically in some ﬁbroblasts of the connective sublining layer.
At sites of calciﬁcation GRP was detected co-localized with the mineral
deposits. The detection of GRP in synoviocytes lead us to investigate the
presence of GRP in the synovial ﬂuid and the results obtained by Western
blot analysis, either using the common or 2-D electrophoresis, pointed to
the existence of several forms of GRP in this body ﬂuid. Cartilage extracts
analyzed by Western blot also showed the presence of several GRP forms.
Altogether these results point to the existence of several forms of GRP in
human.However, PCR ampliﬁcations using different sets of speciﬁc primers
always resulted in the ampliﬁcation of only the F1 isoform andno evidences
were found for the existence of additional GRP spliced transcripts.
Conclusions: Our results show that in OA, GRP is accumulated in the
articular and calciﬁed cartilage, subchondral bone, synovial membrane
and synovial ﬂuid. The detection of GRP co-localized with the ectopic
mineral deposits present in OA, conﬁrms the association of this protein to
pathological calciﬁcations. Furthermore our results show that GRP is also
highly accumulated at sites of inﬂammation associated with OA, and could
indicate an active role of this Gla protein in inﬂammation processes.
Although wewere able to conﬁrm the presence of isoform F1, we found no
evidence for the existence in human of the other 3 alternatively spliced
transcripts of the GRP gene (F2, F3 and F4) described to exist in mouse,
suggesting that the different GRP forms detected by Western blot might
correspond to different g-carboxylation status of the protein.
At the moment a speciﬁc ELISA assay for GRP detection is being developed
and will enable unveiling the relation between levels and forms of GRP in
the synovial ﬂuid with OA severity, providing a new tool that might be
relevant in OA assessment and diagnosis.
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NEW URINE BIOMARKER ASSAY COMPARES TO SYNOVIAL FLUID
CHANGES AFTER ACUTE JOINT INJURY IN AN EQUINE MODEL OF
OSTEOARTHRITIS
T.N. Trumble 1, D.M. Groschen 1, N. Ha 2, M. Boyce 1, K.A. Merritt 3,
M.P. Brown 3. 1Univ. of Minnesota, St. Paul, MN; 2 IBEX Pharmaceutical Inc,
Montreal, QC, CANADA; 3Univ. of Florida, Gainesville, FL
Purpose: It has been well documented that collagenase cleavage of type II
collagen occurs during osteoarthritis (OA) and that neoepitopes created by
this cleavage can be identiﬁed and semi-quantiﬁed in the synovial ﬂuid
(SF) and serum. Recently, a new sandwich assay for urine (IB-C2C-EUSA;
IBEX Pharmaceutical Inc) was developed that detects an intrachain epitope
within 45 residues of the neoepitope on the Carboxy-terminal 3/4 frag-
ment. The purpose of this study was to use this sandwich assay to deter-
mine if acute changes could be identiﬁed in equine urine following
osteochondral (OC) injury and compare the ﬁndings to SF.
Methods: Twenty-two clinically and radiographically normal age- and
sex-matched Quarter Horses were randomly divided into 2 groups: (1)
horses (n¼11) that had an OC fragment created arthroscopically in one
randomly selectedmetacarpophalangeal (MCP) joint and a sham operation
in the contralateral joint at week 0; and (2) unoperated exercise control
horses (n¼11). All horses were exercised on a treadmill from week 2 to
week 16. Urine was collected via catheterization mid-morning in all
horses. Blood was collected from the jugular vein and SF samples were
collected without lavage from both MCP joints of all horses at baseline
(week 0), and weeks 1, 2, 4, 8, 12, and 16. IB-C2C-EUSA kits were provided
by IBEX. Other commercially available ELISA assays were purchased (C2C
[IBEX], CTXII [IDS/Nordic], and MicroVue Creatinine [Quidel Corp]) and
were used to analyze SF and serum or urine samples. IB-C2C-EUSA results
were analyzed with and without creatinine (Cr) correction and the percent
change from baseline was calculated. Normality was assessed and outliersremoved. A repeated measures ANOVA with a Tukey's test for multiple
comparisons was used for all analyses. Correlations between biomarkers
were performed using Spearman Rank. P 0.05 was considered signiﬁcant.
Results: There was a signiﬁcant effect of time (P¼0.003), group (P¼0.013)
and the interaction between group and time (P¼0.006) for the percent
change from baseline of IB-C2C-EUSA concentrations that were not Cr
adjusted (uC2C; Fig 1a). This is similar to SF C2C concentrationswhere there
is also a signiﬁcant effect of time, group, and the interaction (P<0.0001 for
all; Fig 1b). With both assays, OC injured horses had greater change over
time than the control group or shams, as demonstrated by IB-C2C-EUSA
urine samples being signiﬁcantly elevated above baseline and controls at
week 1 and SF C2C samples being elevated above shams and controls from
week1 to week 16 (Fig 1). Adjustment of IB-C2C-EUSA samples with Cr (as
well as percent change) did not allow for any separation between groups.
However, correlation analyses were similar regardless of whether Cr was
adjusted for or not. Cr adjusted IB-C2C-EUSA concentrations were nega-
tively correlated to age (R¼ -0.569; P¼0.0001), SF C2C (R¼ -0.127; P¼0.03),
SF:serum C2C ratio (R¼ -0.152; P¼0.009), and were positively correlated to
urine CTX-II concentrations (R¼0.685; P¼0.0001).
Conclusions: Our results demonstrate that the IB-C2C-EUSA sandwich
assay for equine urine can identify acute changes that occur in response to
injury that is similar to the response identiﬁed in SF. In most equine
biomarker studies, the only changes that occur within one week after
injury to a single limb are in the SF. The results of this study suggest
however, that IB-C2C-EUSA has the potential to identify these early
changes as well, allowing for less invasive testing procedures. Further
investigation will need to be performed to determine future recommen-
dations regarding creatinine adjustment.
Figure 1. a) Percent change from baseline (SD) for IB-C2C-EUSA
concentrations (not Cr adjusted) for osteochondral (OC) injured and
control horses. b) Synovial ﬂuid C2C concentrations for OC injured and
sham limbs, and controls. OC injured to baseline: +++ ¼ P<0.001, ++ ¼
P<0.01; OC injured to sham: *** ¼ P<0.001; OC injured to controls: ^^^ ¼
P<0.001, ^ ¼ P<0.05; sham to control: ## ¼ P<0.01.
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SYNOVIAL FLUID BIOMARKERS OF INNATE IMMUNE ACTIVITY ARE
PREDICTIVE OF KNEE OSTEOARTHRITIS PROGRESSION
P.A. Band 1, H.-G. Wisniewski 1, V. Liublinska 2, C. Pattanayak 2, E. Colon 1,
J. Heeter 3, R. Karia 1, T. Stabler 4, E.A. Balazs 3, V. Kraus 4. 1New York Univ.
